Previous Close | 15.22 |
Open | 15.09 |
Bid | 16.27 x 800 |
Ask | 16.35 x 900 |
Day's Range | 14.51 - 15.29 |
52 Week Range | 6.46 - 35.67 |
Volume | |
Avg. Volume | 4,995,028 |
Market Cap | 2.324B |
Beta (5Y Monthly) | 2.33 |
PE Ratio (TTM) | 167.22 |
EPS (TTM) | 0.09 |
Earnings Date | Apr 29, 2024 - May 03, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 30.43 |
Subscribe to Yahoo Finance Plus to view Fair Value for TGTX
In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado. Abstracts are now available online and can be accessed on the AAN meeting website at htt
NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in West Palm Beach, Florida. Links to each presentation are included below. Michael S. Weiss,